TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna’s mFlusiva, an mRNA flu vaccine approved for adults 50 and older, is available at more than 13,000 locations, but the company says it is making a limited first-year launch. People seeking it can use Moderna’s vaccine finder or call pharmacies, and should not delay vaccination while searching. Evidence comparing its clinical protection with enhanced flu vaccines remains limited.
Moderna’s mFlusiva, the first mRNA flu shot described in the report, is available at more than 13,000 locations in the United States, but the company says its first-season launch is limited. Approved in August for adults ages 50 and older, the vaccine arrived after major pharmacy chains had ordered much of their seasonal flu-shot supply, so people looking for it may need to check Moderna’s vaccine finder or call pharmacies directly, while keeping in mind why timely flu protection matters.
A Moderna spokesperson told MedPage Today that the company planned a “limited launch in year one” and supplied the publication with a link to its vaccine finder. The stated count of locations does not mean every site has doses in stock; the report advises people interested in mFlusiva to check the finder and confirm availability with a pharmacy before traveling, including at local flu and COVID vaccine clinics.
Amesh Adalja, an infectious-disease expert at the Johns Hopkins Center for Health Security, told MedPage Today that patients may have to call around. He said pharmacies often order standard flu vaccines without distinguishing among less common products, a problem he has encountered when seeking vaccines such as Flublok and Flucelvax.
The vaccine is authorized for adults 50 and older, while flu vaccination requirements also apply to military recruits. The FDA granted traditional approval for people ages 50 to 64 and accelerated approval for those 65 and older, with a postmarketing effectiveness study planned for the older group. The report does not name particular pharmacies or give a location-by-location inventory, so availability needs to be confirmed locally.
Finding a Dose Without Delaying Vaccination
For adults who specifically want an mRNA flu vaccine, limited supply and the timing of approval may make it harder to find than a standard flu shot. A search could take extra calls, while local pharmacies may have already committed much of their seasonal inventory to other products.
But the report does not establish that mFlusiva is clinically superior to other available flu vaccines. Direct outcome comparisons with enhanced vaccines are lacking, and the FDA requires further effectiveness evidence for people 65 and older. That makes the practical choice a balance among what is available, personal preference and a clinician’s advice—not a reason to put off vaccination while hunting for one particular brand.
William Schaffner of Vanderbilt University, a spokesperson for the Infectious Diseases Society of America, said influenza had started early in many parts of the country. His advice was to get a vaccine that is available rather than wait for a preferred product. People with questions about which vaccine is appropriate for them can ask a health professional.
As an affiliate, we earn on qualifying purchases.
How mFlusiva Fits the Flu Vaccine Market
U.S. flu vaccination includes several types of products, not just the new mRNA option. Standard-dose vaccines are generally made using eggs; other choices include the nasal-spray FluMist, cell-based Flucelvax and recombinant Flublok. For people 65 and older, options also include Fluzone High-Dose and the adjuvanted vaccine Fluad. Product eligibility and availability vary, so patients should confirm details with a provider or pharmacy.
The late approval helps explain the first-season supply constraints: Moderna’s shot was approved in August, after retail pharmacy chains had placed orders for this season. The report says all U.S. flu vaccines are now trivalent, following the CDC’s determination that the B/Yamagata lineage had stopped circulating after March 2020.
Evidence is still developing. A phase III study compared mFlusiva with a standard-dose vaccine, while a separate study in adults 65 and older found a stronger immune response than Fluzone High-Dose but did not assess clinical outcomes. An immune response is not, by itself, proof of better protection against illness.
““If someone wants to get mFlusiva, they’re going to have to use that website or call around.””
— Amesh Adalja, Johns Hopkins Center for Health Security
As an affiliate, we earn on qualifying purchases.
Supply and Protection Evidence Still Developing
The report does not provide a real-time inventory or identify which pharmacies currently have mFlusiva in stock. The company’s count of more than 13,000 locations indicates distribution, not guaranteed availability at each location. People should check with a pharmacy before making a trip.
It also remains unclear whether mFlusiva provides better clinical protection than enhanced flu vaccines such as Flublok or Fluzone High-Dose. The cited studies do not offer a head-to-head comparison of clinical outcomes against those products. The FDA’s accelerated approval for adults 65 and older is tied to a planned postmarketing effectiveness study; the report gives no schedule or results for that work.
Trial data cited in the report found more injection-site pain, fatigue, headache and muscle aches with mFlusiva than with standard-dose flu shots. Schaffner said he would expect more reactions than with enhanced vaccines as well, but that comparison has not been established in the material provided. Individual response and the balance of benefits and side effects remain matters to discuss with a health professional.
As an affiliate, we earn on qualifying purchases.
Check Local Stock and Watch for Study Results
Adults 50 and older who want mFlusiva can start with Moderna’s vaccine finder, then call a listed pharmacy to confirm that doses are available and ask about appointment requirements. If it is not in stock, patients can discuss other age-appropriate flu vaccines with a pharmacist or clinician rather than wait without a vaccination plan.
The next evidence milestone is the postmarketing effectiveness study required for adults 65 and older. Results could help clarify how mFlusiva performs in real-world clinical terms compared with other options, but the report does not provide a completion date. For now, local supply and the patient’s age and health circumstances will shape the available choice.
As an affiliate, we earn on qualifying purchases.
Key Questions
Where can I find mFlusiva?
Use the vaccine finder linked by Moderna, then contact the listed pharmacy to confirm it has doses. The company says the shot is available at more than 13,000 locations, but stock may vary.
Who is eligible for the mRNA flu shot?
The FDA approved mFlusiva for adults ages 50 and older. The approval is traditional for ages 50 to 64 and accelerated for people 65 and older.
Why may mFlusiva be hard to find?
Moderna described this as a limited first-year launch. The shot was approved in August, after major retail pharmacy chains had placed orders for the season, according to the report.
Is mFlusiva proven to work better than other flu shots?
The available evidence described in the report does not establish better clinical protection than enhanced flu vaccines. A study found a stronger immune response than Fluzone High-Dose in adults 65 and older, but it did not measure clinical outcomes.
Should I wait until I find mFlusiva?
Schaffner advised people not to delay vaccination while seeking a specific product, citing early influenza activity in parts of the country. Ask a pharmacist or clinician about an available vaccine that is appropriate for you.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
